Compound Screening TRIZ Cases

Measures how test compounds partition into target condensates, enabling rational design of therapeutics with desired potency and safety.

Phase-separation assays reveal how test compounds enrich or deplete in biological condensates, guiding compound design and selection.

Sequential DESI-MS spot analysis enables label-free enzyme screening with rapid product detection, kinetic measurement, and inhibitor assessment.

Dual CID/HCD phosphoproteomics and PPI outlier analysis expand phosphopeptide coverage and improve drug efficacy prediction.

Competitive binding with limited capture molecules and LC-MS screens biologic variants in one workflow, improving CQA assessment throughput.

Tumor organoid co-cultures with immune cells and IL-2 media improve patient-specific drug screening while reducing donor variability.

Multiple antibodies targeting non-overlapping spike epitopes curb SARS-CoV-2 escape mutants while maintaining antiviral efficacy.

Specific anti-PD-L1 epitope binding improves detection of tumor PD-L1 expression and helps identify patients for PD-1 axis therapy.

Blocking GDF-15 helps restore CD8+ T-cell activity and improves immune checkpoint blocker response in solid cancer treatment.

Nuclear and cytoplasmic NMT1 plus NMT2 localization improve ER+ breast cancer prognosis and help identify endocrine resistance.

A diversified SPINK2 peptide library enables screening of high-affinity binders to proteases and other disease-related targets.

Targeting FKBP1A offers a tumor-specific route for triple-negative breast cancer, improving apoptosis, differentiation, and diagnostic precision.

Time-lapse cell imaging tracks morphological changes and early markers across heterogeneous cells, improving assay efficiency in drug discovery.

Radiolabeled and fluorescent HSP90 inhibitors enable non-invasive tumor profiling to predict response and guide dosing while reducing unnecessary toxicity.

Targets the N-terminal sequence that remains after mutant CALR cleavage, improving myeloproliferative neoplasm detection and therapy.

OR-GFP binding to retro-transcribed ANCH3-tagged viral DNA enables live-cell HIV-1 genome imaging without disrupting morphology or viability.

Resurfaced IL-2 variants shift receptor binding to selectively activate Tregs or block overactivation, reducing toxicity and dosing burden.

High-throughput tumor organoid screening combines confocal fluorescence imaging and statistical analysis to predict drug response with reproducibility.

A cell-free steroid receptor assay detects active ligands through T7 polymerase transcription or fluorescence inhibition without nuclear extracts.

Blocking PVRIG-PVRL2 binding with anti-PVRIG antibodies boosts T-cell activation and cancer cell cytotoxicity while reducing immune tolerance.

A cell-free steroid receptor assay detects bioactive ligands by measuring inhibited reporter transcription without nuclear extracts or complex equipment.

Targeting the VAP-A, ORP3, and Rab7 complex disrupts intercellular signaling and blocks endocytosed disease material from reaching cell nuclei.

CH3-domain IgG1 substitutions block ICAM-1/CD54 Fc binding, restoring ADCC, ADCP, CDC, and ADC internalization in tumors.

Microfluidic in vitro screening and iterative machine learning tune antimicrobial peptides for precise activity under specific culture conditions.

A human sebaceous gland progenitor cell line enables stable lipid-response testing and more accurate screening of oil-regulating drugs and skincare products.

Targeted Fc mutations improve plasma retention while reducing pre-existing ADA binding and preserving rapid IL-8 antigen elimination.

Measuring intracellular osteopontin in follicular T cells improves autoimmune and T cell lymphoma diagnosis while simplifying detection with optical assays.

Nanobodies that bind G proteins stabilize active GPCR:G protein complexes, enabling structure analysis and more effective drug screening.

Microbially produced GOS targets Lactobacillus strains to improve probiotic survival and selective gut colonization.

Flowing therapeutic reagents over cultured cells in microfluidic channels recreates shear stress and gas conditions for more representative assay results.

YTHDF2 inhibition expands HSCs while preserving self-renewal and multilineage potential, supporting faster immune recovery after transplantation.

βII spectrin fragment immunoassays improve early cardiac risk detection and disease monitoring when general inflammation markers lack specificity.

A specialized medium with Y27632, A8301, growth factors, and serum enables rapid primary intestinal cancer cell expansion while preserving pathology.

Exogenous promoters and tuned GPCR effector expression cut leaky background, improving signal-to-background ratio and assay consistency.

Covalent small molecules target the Switch 2 pocket and mutant K-RasG12C residues to improve inhibition while limiting proto-oncogenic binding.

Glutathione-related gene and protein markers help identify platinum NAC resistance in solid tumors before treatment, guiding patient selection.

Automated specimen plate and contact patch motion enables uniform blood smearing and staining with less operator skill and fewer manual errors.

Preloaded micro-cavities deliver staining reagent by capillary action, enabling faster direct blood observation with less manual work and reagent use.

FCS brightness analysis quantifies dyes on extracellular vesicles, overcoming unstable labeling and enabling accurate biodistribution evaluation.

Fluorescent RET with labeled GTP analogues measures GPCR activation by G-protein subtype without radioactivity, washing, or separate membranes.

BMP species measurements help identify responsive patients and track dosing effects in progranulin-associated disorders.

By replacing EGF with IGF1, FGF2, and EREG, this medium supports long-term organoid culture while preserving EGFR expression and differentiation.

Short selective ACKR3 peptides recruit β-arrestin to regulate endogenous opioid peptide levels without direct opioid receptor activation.

CSF-1 co-culture turns primitive-like macrophages into microglia within brain organoids, creating a human-relevant model for CNS research.

Targeting CDK1-driven TERT phosphorylation at key residues disrupts RdRP activity in cancer stem cells and supports inhibitor screening.

TPK targeting enables Alzheimer's animal models that reproduce glucose metabolism disorders, neurodegeneration, and cognitive decline.

Targeting the HK1b isoform with CRISPR or siRNA suppresses NSCLC growth while sparing normal metabolism and improving chemotherapy response.

Chronic weak oxidative stress in antioxidant-free stem cell-derived neurons reproduces progressive damage for neurodegeneration drug screening.

Vinyl sulfone-thiol microfluidic crosslinking improves hydrogel bead stability and uniform cell encapsulation for prolonged culture and screening.

Targeting the piR-hsa-164586 and MYH9 interaction offers a route to suppress NSCLC cell migration and metastasis.

Automated patch and specimen plate motion improves blood smear uniformity and staining accuracy for reliable testing in resource-limited settings.

Patient-matched normal-cell filtration removes cross-reactive xenoantibodies, improving neoantigen targeting while sparing healthy cells.

Chemical reprogramming of hepatocytes plus CRISPR TP53/BAP1 knockout enables faster biliary cancer organoid production for modeling and drug screening.

Low-dose CD19 CAR-T and CAR-NK cells target pathogenic B cells to relieve autoimmune symptoms with longer-lasting control and fewer administrations.

Detecting a partial-EMT gene signature stratifies HNSCC patients by metastasis risk and supports demographic-specific treatment selection.

Membrane-permeable inducers control protein dimerization and TAA expression, enabling more reliable on-target, off-tumor screening.

Machine-learning-guided screening links peptide sequences to inhibition data, targeting potency across microbial strains and culture conditions.

FGF and TGF-beta3 guide staged stem cell differentiation and orbital culture to produce accurate ECM for regeneration and disease modeling.

This case uses Ait1-mediated TORC1 regulation to disrupt yeast growth transitions and address multidrug-resistant Candida infections.

This case uses high-affinity antibodies against the NMDA receptor NR1 subunit to block autoantibody binding in CNS disorders.

Cell-based assay identifies agents reducing amyloid beta cytotoxicity through direct toxicity measurement.

Porous membrane inserts simulate biological barriers to detect active immune cell migration and cytotoxicity within 3D tumor spheroids.

Acetonitrile precipitation and online dilution resolve sensitivity limits for LSD microdoses, enabling accurate pharmacokinetic monitoring.

Bifunctional compounds link estrogen receptor alpha to ubiquitin ligase via a linker to induce targeted proteasomal degradation.

An ex vivo cell culture system co-cultures patient-derived leukemia cells with stromal cells to measure drug responses.

A phase transition adjusting kit drives liquid-liquid phase separation to concentrate multivalent ligands and enhance cell surface molecule oligomerization.

A photoreactive synthetic regulator uses photoisomerizable groups to modulate protein function via light exposure.

Luciferin derivatives act as substrates for nonluciferase enzymes, expanding applicability beyond native luciferase reactions.

A screening method identifies anticancer agents that inhibit the binding of AIMP2-DX2 and HSP70 proteins.

X-ray diffraction determines the CD147 extracellular region structure to identify active sites for structure-based drug design.

Expressing cyclin F via viral vectors clears abnormal TDP-43 accumulation and prevents neurodegeneration in ALS and FTD models.